Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.